Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-11-01
2005-11-01
Housel, James (Department: 1648)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S043000, C514S046000, C514S023000, C514S027000, C536S023700, C536S023720, C536S028600, C536S028700, C536S029100, C424S093100, C424S093200, C424S185100, C435S091210, C435S320100, C435S325000
Reexamination Certificate
active
06960569
ABSTRACT:
Disclosed herein is the discovery of a novel hepatitis C virus (HCV) isolated from a human patient. Embodiments of the inevntion include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as, methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.
REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 4950647 (1990-08-01), Robins et al.
patent: 5350671 (1994-09-01), Houghton et al.
patent: 5371017 (1994-12-01), Houghton et al.
patent: 5372928 (1994-12-01), Miyamura et al.
patent: 5585258 (1996-12-01), Houghton et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5597691 (1997-01-01), Houghton et al.
patent: 5670152 (1997-09-01), Weiner et al.
patent: 5670153 (1997-09-01), Weiner et al.
patent: 5679342 (1997-10-01), Houghton et al.
patent: 5683864 (1997-11-01), Houghton et al.
patent: 5698390 (1997-12-01), Houghton et al.
patent: 5712087 (1998-01-01), Houghton et al.
patent: 5712088 (1998-01-01), Houghton et al.
patent: 5712145 (1998-01-01), Houghton et al.
patent: 5714596 (1998-02-01), Houghton et al.
patent: 5728520 (1998-03-01), Weiner et al.
patent: 5756312 (1998-05-01), Weiner et al.
patent: 5766845 (1998-06-01), Weiner et al.
patent: 5767097 (1998-06-01), Tam
patent: 5856437 (1999-01-01), Miyamura et al.
patent: 5863719 (1999-01-01), Houghton et al.
patent: 5871903 (1999-02-01), Miyamura et al.
patent: 5879904 (1999-03-01), Brechot et al.
patent: 5885799 (1999-03-01), Houghton et al.
patent: 5932556 (1999-08-01), Tam
patent: 5942234 (1999-08-01), Ralston et al.
patent: 5959092 (1999-09-01), Miyamura et al.
patent: 5968775 (1999-10-01), Houghton et al.
patent: 5989905 (1999-11-01), Houghton et al.
patent: 6027729 (2000-02-01), Houghton et al.
patent: 6056961 (2000-05-01), Lavie et al.
patent: 6060068 (2000-05-01), Doyle et al.
patent: 6063380 (2000-05-01), Chedid et al.
patent: 6063772 (2000-05-01), Tam
patent: 6071693 (2000-06-01), Cha et al.
patent: 6074816 (2000-06-01), Houghton et al.
patent: 6074846 (2000-06-01), Ralston et al.
patent: 6074852 (2000-06-01), Ralston et al.
patent: 6096541 (2000-08-01), Houghton et al.
patent: 6130326 (2000-10-01), Ramasamy et al.
patent: 6150087 (2000-11-01), Chien
patent: 6150337 (2000-11-01), Tam
patent: 6153421 (2000-11-01), Yanagi et al.
patent: 6171782 (2001-01-01), Houghton et al.
patent: 6190864 (2001-02-01), Cha et al.
patent: 6194140 (2001-02-01), Houghton et al.
patent: 6214583 (2001-04-01), Cha et al.
patent: 6235888 (2001-05-01), Pachuk et al.
patent: 6274148 (2001-08-01), Ralston et al.
patent: 6297370 (2001-10-01), Cha et al.
patent: 6303292 (2001-10-01), Weiner et al.
patent: 6312889 (2001-11-01), Houghton et al.
patent: 6514731 (2003-02-01), Valenzuela et al.
patent: 6541011 (2003-04-01), Punnonen et al.
patent: 6653125 (2003-11-01), Donnelly et al.
patent: 2002/0004048 (2002-01-01), Ralston et al.
patent: 2002/0165172 (2002-11-01), Sallberg et al.
patent: 2002/0183508 (2002-12-01), Maertens et al.
patent: 2002/0187945 (2002-12-01), Tam
patent: 2003/0007977 (2003-01-01), Wheeler et al.
patent: 2003/0008274 (2003-01-01), Maertens et al.
patent: 2003/0032005 (2003-02-01), Maertens et al.
patent: 0 318 216 (1989-05-01), None
patent: 0 388 232 (1990-09-01), None
patent: 0 414 475 (1991-02-01), None
patent: 0 450 931 (1996-06-01), None
patent: 0 543 924 (1997-06-01), None
patent: 0 842 947 (1998-05-01), None
patent: 0 693 687 (1999-07-01), None
patent: 0 556 292 (1999-12-01), None
patent: 1 034 785 (2000-09-01), None
patent: 0 318 216 (2001-08-01), None
patent: 0 398 748 (2002-01-01), None
patent: WO 91/15575 (1991-10-01), None
patent: WO 92/19743 (1992-11-01), None
patent: WO 93/00365 (1993-01-01), None
patent: WO 93/06126 (1993-04-01), None
patent: WO 94/16737 (1994-08-01), None
patent: WO 96/09805 (1996-04-01), None
patent: WO 96/28162 (1996-09-01), None
patent: WO 97/12043 (1997-04-01), None
patent: WO 97/26883 (1997-07-01), None
patent: WO 97/47358 (1997-12-01), None
patent: WO 98/16184 (1998-04-01), None
patent: WO 98/16186 (1998-04-01), None
patent: WO 98/30223 (1998-07-01), None
patent: WO 98/34640 (1998-08-01), None
patent: WO 98/37180 (1998-08-01), None
patent: WO 99/04008 (1999-01-01), None
patent: WO 99/28482 (1999-06-01), None
patent: WO 00/44388 (2000-08-01), None
patent: WO 01/38360 (2001-05-01), None
patent: WO 01/96875 (2001-12-01), None
patent: WO 02/13855 (2002-02-01), None
patent: WO 02/14362 (2002-02-01), None
patent: WO 03/031588 (2003-04-01), None
patent: WO 03/031588 (2003-04-01), None
Lohman et al. Science 1999, vol. 285, pp. 110-113.
Forns et al. P.N.A.S. USA 2000, vol. 97, pp. 13318-13323.
AASLD Abstracts 940, “Hepatitis C Virus NS5A Sequence Confirugation does not Predict Response to Induction Interferon Plus Ribavirin,”Hepatology,p. 394A (2000).
Chen et al., “Human and Murine Antibody Recognition is Focused on the ATPase/Helicase, but not the Protease Domain of the Hepatitis C Virus Nonstructural 3 Protein,”Hepatology,28(1):219-224 (1998).
Chen et al., “Detection of Hepatitis C Virus RNA in the Cell Fraction of Saliva Before and After Oral Surgery,”J. Med. Virol.,43:223-226 (1995).
Chiang et al., “Enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response by ribavirin correlates with the increased level of IL-2,”Vaccine Strategies Against Microbial Pathogens,42.11-42.16, p. A949 (date unknown).
Cotonat et al., “Pilot Study of Combination Therapy with Ribavirin and Interferon Alfa for the Retreatment of Chronic Hepatitis B e Antibody-Positive Patients,”Hepatology,31(2):502-506 (2000).
Cramp et al., “Hepatitis C Virus-Specific T-Cell Reactivity During Intereron and Ribavirin Treatment in Chronic Hepatitis C,”Gastron. Enterol.,118:346-355 (2000).
Encke et al., “Genetic Immunization Generates Cellular and Humoral Immune Responses Against the Nonstructural Proteins of the Hepatitis C Virus in a Murine Model”,Journal of Immunology,161:4917-4923 (1998).
Diepolder et al., “Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection,”Lancet,346(8981):1006-1007.
Gordon et al., “Immune responses to hepatitis C virus structural and nonstructural proteins induced byplasmid DNA immunizations,”Journal of Infectious Diseases,181(1):42-50.
Hsu et al., “Prospects for a Hepatitis C Virus Vaccine”,Clin Liver Dis,3(4):901-915 (1999).
Huffman et al., “In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses,”Antimicrob. Agents. Chemother.,3(2):235 (1973).
Jin et al., “Expression, isolation, and characterization of the hepatitis C virus ATPase/RNA Helicase,”Arch. Biochem. Bioplys.,323:47-53 (1995).
Kakumu et al., “Pilot Study of Ribavirin and Interferon- for Chronic Hepatitis B,”Hepatology,18(2):258-263 (1993).
Kato, “Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation,”Microb. Com. Genomics,5(3):129-151 (2000).
Kwong et al., “Hepatitis C virus NS3/4A protease,”Antiviral Res.,41(1):67-84 (1999).
Kwong et al., “Structure and function of hepatitis C virus NS3 helicase,”Curr. Top. Microbiol. Immunol.,242:171-196 (2000).
Lawrence et al., “Advances in the treatment of hepatitis C,”Adv. Intern. Med.,45:65-105 (2000).
Li et al., “Role of the guanosine triphosphatase Rac2 in T helper 1 cell differentiation,”Science,288:2219-2222 (2000).
Marquardt et al., “Ribavirin inhibits mast cell mediator release,”J. Pharmacol. Exp. Therapeutics,240(1):145-149 (1987).
Marshall et al., “Detection of HCV RNA by the asymmetric gap ligase chain reaction,”PCR Methods and Applications,4(2):80-84 (1994).
Memar
Housel James
Knobbe Martens Olson & Bear LLP
Li Bao Qun
TRIPEP AB
LandOfFree
Hepatitis C virus non-structural NS3/4A fusion gene does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hepatitis C virus non-structural NS3/4A fusion gene, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepatitis C virus non-structural NS3/4A fusion gene will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3475509